MED vs JVA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 13, 2026

MED

42.7
AI Score
VS
JVA Wins

JVA

46.1
AI Score

Investment Advisor Scores

MED

43score
Recommendation
HOLD

JVA

46score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MED JVA Winner
Revenue 152.43M 69.38M MED
Net Income -5.22M 3.90M JVA
Gross Margin 69.0% 21.7% MED
Net Margin -3.4% 5.6% JVA
Operating Income -7.62M 5.04M JVA
ROE -2.7% 12.6% JVA
ROA -2.0% 9.7% JVA
Total Assets 260.40M 40.18M MED
Cash 71.91M 2.92M MED
Current Ratio 4.86 4.14 MED
Free Cash Flow -108,000 7.71M JVA

Relative Price Performance (Last 90 Days)

MED 1M: +3.9% · 3M: +1.0% JVA 1M: +8.9% · 3M: -8.2%

Current Technical Phase

MED

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.4% over 20 days), RSI 53

RSI (14): 52.8 · Price: $12.04

JVA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 72

RSI (14): 72.3 · Price: $3.86

Fundamentals Snapshot

Metric MED JVA
Market Cap
Forward P/E -43.0 13.4
Trailing P/E 12.7
Revenue (TTM)
Revenue Growth -0.3% -0.1%
Gross Margin 0.7% 0.2%
Operating Margin -0.1% 0.0%
EPS -2.31 0.27
Dividend Yield 0.02%

Frequently Asked Questions

Based on our detailed analysis, JVA is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.